SCHEMBL4874221

SCHEMBL4874221

Cc1ccc(NC2=C(N3CCCC3)C(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APAF1 O14727 11/20 0.97
▸ NPC1 O15118 6/20 0.97
▸ RAB9A P51151 5/20 0.97
▸ MAPT P10636 13/20 0.78
▸ ALDH1A1 P00352 11/20 0.78
▸ L3MBTL1 Q9Y468 7/20 0.78
▸ SMN1; SMN2 Q16637 6/20 0.78
▸ POLB P06746 5/20 0.78
▸ KDM4E B2RXH2 4/20 0.78
▸ HPGD P15428 2/20 0.78
▸ HTT P42858 6/20 0.76
▸ LMNA P02545 4/20 0.76
▸ MITF O75030 4/20 0.76
▸ KLF5 Q13887 1/20 0.76
▸ CDC25A P30304 2/20 0.67
▸ CDC25B P30305 2/20 0.67
▸ MEN1 O00255 7/20 0.61
▸ KMT2A Q03164 7/20 0.61
▸ GAA P10253 4/20 0.61
▸ NPSR1 Q6W5P4 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5807881 0.99 APAF1 (1.00) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL7247303 0.88 MAPT (0.97) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16297187 0.87 APAF1 (1.00) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL7246128 0.86 MAPT (0.76) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL4872810 0.86 MAPT (0.76) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16297041 0.86 MAPT (0.76) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL7247910 0.86 APAF1 (0.76) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL24355094 0.85 MITF (0.73) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL2464285 0.85 APAF1 (0.72) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL7243360 0.85 APAF1 (0.72) APAF1NPC1RAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513437-B2 Pyrrolidino-1,4-naphthoquinone deriviatives and their use for treating malignancies and cardiovascular diseases BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IS) 2013-08-20 — — US disclosed
US-20080300274-A1 Novel Pyrrolidino-1,4-Naphthoquinone Deriviatives and their Use for Treating Malignancies and Cardiovascular Diseases BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) 2008-12-04 — — US disclosed
WO-2006011136-A9 NOVEL NAPHTHOQUINONE DERIVATIVES AND USES THEREOF VELOPMENT AUTHORITY BEN GURION (IL) 2006-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300274-A1 Novel Pyrrolidino-1,4-Naphthoquinone Deriviatives and their Use for Treating Malignancies and Cardiovascular Diseases MAPK1, MAP3K1, MAP3K20 APAF1 1872/4885NPC1 1969/4885RAB9A 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback